50-32-227. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule III. The board may except by rule any compound, mixture, or preparation containing any stimulant or depressant drug listed in 50-32-226(1) and (2) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the drugs which have a stimulant or depressant effect on the central nervous system.
History: En. Sec. 9, Ch. 412, L. 1973; R.C.M. 1947, 54-309(5).
Structure Montana Code Annotated
Chapter 32. Controlled Substances
Part 2. Scheduling of Dangerous Drugs
50-32-201. General criteria to be considered
50-32-202. Designation of drug as dangerous drug
50-32-203. Effect of rescheduling under federal law
50-32-204. Immediate precursors
50-32-205. Nonprescription drugs not to be scheduled
50-32-206. Use of names of scheduled drugs
50-32-207. Order forms for drugs in Schedules I and II
50-32-208. Prescription and medical requirements for scheduled drugs -- penalty
50-32-209. Republication of schedules
50-32-210. through 50-32-220 reserved
50-32-221. Criteria for placement of drug in Schedule I
50-32-222. Specific dangerous drugs included in Schedule I
50-32-223. Criteria for placement of drug in Schedule II
50-32-224. Specific dangerous drugs included in Schedule II
50-32-225. Criteria for placement of drug in Schedule III
50-32-226. Specific dangerous drugs included in Schedule III
50-32-227. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule III
50-32-228. Criteria for placement of drug in Schedule IV
50-32-229. Specific dangerous drugs included in Schedule IV
50-32-230. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule IV
50-32-231. Criteria for placement of drug in Schedule V